학술논문
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Document Type
Article
Author
Lu, Shun ; Wu, Lin; Jian, Hong; Chen, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Sun, Meili; Han, Liang; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Li, Baolan; Pan, Yueyin; Li, Xingya; Ye, Feng; Liu, Anwen; Wang, Ke; Cang, Shundong; Zhou, Hui; Sun, Xing; Ferry, David; Lin, Yong; Wang, Shuyan; Zhang, Wen; Zhang, Chengli
Source
In The Lancet Oncology September 2022 23(9):1167-1179
Subject
Language
ISSN
1470-2045